Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
By Phase
1 drugs in development
By Therapeutic Area
top 1
R&D Momentum
27/100
Pipeline Velocity
6/100
Trial Completion Rate
81/100
Pipeline Concentration
100/100
Pipeline Freshness
100/100
Activity
Last 14 days
Expanded Access Study for Renal Transplant Patients With Envarsus XR ™
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Regulatory
Prograf — PROGRAF
Application NDA050709 (NDA)
Prograf — PROGRAF
Application NDA050708 (NDA)
Prograf — PROTOPIC
Application NDA050777 (NDA)
Prograf — ASTAGRAF XL
Application NDA204096 (NDA)
Prograf — ENVARSUS XR
Application NDA206406 (NDA)
Prograf — PROGRAF
Application NDA210115 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)